

JosÃ© F Corona-Cruz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/424952/publications.pdf>

Version: 2024-02-01

20
papers

496
citations

840776

11
h-index

839539

18
g-index

23
all docs

23
docs citations

23
times ranked

879
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Depression and Anxiety on Quality of Life, Treatment Adherence, and Prognosis in Patients with Advanced Non-small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 1941-1948.	1.5	235
2	Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study. <i>Lung Cancer</i> , 2019, 130, 67-75.	2.0	40
3	First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. <i>British Journal of Cancer</i> , 2012, 106, 1027-1032.	6.4	39
4	A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 975-982.	2.3	25
5	Survival of Patients with Advanced Non-Small Cell Lung Cancer Enrolled in Clinical Trials. <i>Oncology</i> , 2016, 91, 185-193.	1.9	19
6	Lung metastasectomy: Long-term outcomes in an 18-year cohort from a single center. <i>Surgical Oncology</i> , 2012, 21, 237-244.	1.6	17
7	Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103033.	4.4	17
8	Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. <i>Lung Cancer</i> , 2021, 152, 119-126.	2.0	17
9	Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico. <i>Tobacco Induced Diseases</i> , 2015, 12, 25.	0.6	14
10	Diagnostic efficacy of electron microscopy and pleural effusion cytology for the distinction of pleural mesothelioma and lung adenocarcinoma. <i>Ultrastructural Pathology</i> , 2016, 40, 254-260.	0.9	8
11	Radical aggressive treatment among non-small cell lung cancer patients with malignant pleural effusion without extra-thoracic disease. <i>Journal of Thoracic Disease</i> , 2019, 11, 595-601.	1.4	8
12	Proposals for the prevention of lung cancer in the health system of Mexico. <i>Salud Publica De Mexico</i> , 2016, 58, 274-278.	0.4	5
13	Extended resections of large thymomas: importance of en-bloc thymectomy. <i>Journal of Thoracic Disease</i> , 2018, 10, 3473-3481.	1.4	4
14	Locoregional control and toxicity after pleurectomy/decortication and intensity-modulated pleural radiation therapy in patients with malignant pleural mesothelioma. <i>Thoracic Cancer</i> , 2020, 11, 3448-3455.	1.9	1
15	Surgical care of thoracic malignancies during the COVID-19 pandemic in Mexico: An expert consensus guideline from the Sociedad Mexicana de Oncología (SMeO) and the Sociedad Mexicana de Cirujanos Torácicos Generales (SMCTG). <i>Thoracic Cancer</i> , 2020, 11, 2370-2375.	1.9	1
16	Outcomes after pericardial window surgery (PWS) for palliation of malignant pericardial effusion (MPE).. <i>Journal of Clinical Oncology</i> , 2018, 36, e22193-e22193.	1.6	1
17	HOLA COVID-19 Study: Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America. <i>JCO Global Oncology</i> , 2022, 8, e2100251.	1.8	1
18	MA 16.12 Prolonged Survival after Pulmonary Metastasectomy for Testicular Germ-cell Tumors in a Single Institution. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1870-S1871.	1.1	0

#	ARTICLE	IF	CITATIONS
19	Prolonged survival (SV) associated with pulmonary metastasectomy (PM) for carcinomas of the cervix (CC). Annals of Oncology, 2018, 29, viii351.	1.2	0
20	Long survival (SV) for metastatic renal cell cancer (mRCC) after cytoreductive nephrectomy (CN) plus lung metastasectomy (LM) without targeted therapy (TT).. Journal of Clinical Oncology, 2018, 36, e16564-e16564.	1.6	0